Amicus Therapeutics, Inc. (NASDAQ:FOLD)‘s stock had its “overweight” rating restated by research analysts at J P Morgan Chase & Co in a report released on Wednesday.

A number of other brokerages have also recently commented on FOLD. Zacks Investment Research raised Amicus Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, July 19th. BidaskClub cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, August 11th. Chardan Capital reissued a “buy” rating and issued a $16.50 price objective (down previously from $17.50) on shares of Amicus Therapeutics in a research note on Wednesday, September 13th. Robert W. Baird raised their price objective on Amicus Therapeutics from $12.00 to $15.00 and gave the company an “outperform” rating in a research note on Wednesday, July 12th. Finally, Cowen and Company reissued an “outperform” rating and issued a $18.00 price objective (up previously from $16.00) on shares of Amicus Therapeutics in a research note on Thursday, September 14th. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Amicus Therapeutics has a consensus rating of “Buy” and a consensus price target of $17.92.

Amicus Therapeutics (NASDAQ FOLD) traded up 9.21% during midday trading on Wednesday, reaching $16.24. The company’s stock had a trading volume of 10,582,890 shares. Amicus Therapeutics has a 52-week low of $4.41 and a 52-week high of $16.60. The firm has a 50 day moving average of $13.82 and a 200 day moving average of $10.45. The firm’s market cap is $2.67 billion.

Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings data on Monday, August 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.37) by $0.03. Amicus Therapeutics had a negative return on equity of 61.25% and a negative net margin of 1,279.88%. The firm had revenue of $7.16 million during the quarter, compared to analysts’ expectations of $6.96 million. During the same quarter last year, the firm posted ($0.40) earnings per share. Analysts anticipate that Amicus Therapeutics will post ($1.31) earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This article was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this article on another site, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this article can be viewed at https://www.americanbankingnews.com/2017/10/04/amicus-therapeutics-inc-fold-stock-rating-reaffirmed-by-j-p-morgan-chase-co.html.

In related news, major shareholder Life Sciences Maste Perceptive bought 1,500,000 shares of the business’s stock in a transaction that occurred on Thursday, July 13th. The shares were bought at an average price of $12.25 per share, with a total value of $18,375,000.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 3.40% of the stock is owned by insiders.

Several large investors have recently made changes to their positions in FOLD. Nationwide Fund Advisors boosted its position in shares of Amicus Therapeutics by 11.5% during the first quarter. Nationwide Fund Advisors now owns 131,945 shares of the biopharmaceutical company’s stock valued at $941,000 after buying an additional 13,563 shares during the last quarter. Russell Investments Group Ltd. boosted its position in shares of Amicus Therapeutics by 1,004.9% during the first quarter. Russell Investments Group Ltd. now owns 121,338 shares of the biopharmaceutical company’s stock valued at $865,000 after buying an additional 110,356 shares during the last quarter. Wells Fargo & Company MN boosted its position in shares of Amicus Therapeutics by 51.7% during the first quarter. Wells Fargo & Company MN now owns 153,473 shares of the biopharmaceutical company’s stock valued at $1,094,000 after buying an additional 52,287 shares during the last quarter. Bank of New York Mellon Corp boosted its position in shares of Amicus Therapeutics by 12.5% during the first quarter. Bank of New York Mellon Corp now owns 672,463 shares of the biopharmaceutical company’s stock valued at $4,794,000 after buying an additional 74,700 shares during the last quarter. Finally, UBS Asset Management Americas Inc. boosted its position in shares of Amicus Therapeutics by 71.8% during the first quarter. UBS Asset Management Americas Inc. now owns 50,674 shares of the biopharmaceutical company’s stock valued at $361,000 after buying an additional 21,174 shares during the last quarter.

About Amicus Therapeutics

Amicus Therapeutics, Inc is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease.

Analyst Recommendations for Amicus Therapeutics (NASDAQ:FOLD)

Receive News & Ratings for Amicus Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.